08:00 , Jan 4, 2016 |  BioCentury  |  Finance

Big band swing

Many investors treated biotech's dismal 3Q15 as a buying opportunity, and the effects were apparent in 4Q15. All of the market cap bands showed positive gains save for the microcaps. Big biotechs led the charge...
07:00 , Sep 1, 2014 |  BC Week In Review  |  Company News

BTG sales and marketing update

BTG launched Varithena in the U.S. to treat varicose veins. The wholesale acquisition cost (WAC) for a 45 mL tube of 10 mg/mL Varithena is $3,195. The polidocanol endovenous microfoam ( PEM ) is administered...
08:00 , Jan 13, 2014 |  BioCentury  |  Finance

Buyside View XXII: 'Grown up' means growth

Stephen Hansen Senior Writer  An increase in regulatory approvals and new breakthrough therapies has money managers buying into the concept that biotech has entered a new product cycle that provides a strong fundamental basis for...
08:00 , Jan 6, 2014 |  BioCentury  |  Finance

4Q Stock Wrap-Up: All's well that ends well

Although two segments lost ground in 4Q13, all of biotech's market cap groups finished 2013 in the black. Large caps valued at more than $5 billion led the way in the fourth quarter, tacking on...
08:00 , Dec 9, 2013 |  BC Week In Review  |  Clinical News

Varithena regulatory update

FDA approved an NDA from BTG for Varithena to treat varicose veins. BTG plans to launch the polidocanol endovenous microfoam ( PEM ) in the U.S. in 2Q14 BTG plc (LSE:BTG), London, U.K.   Product:...
01:10 , Nov 27, 2013 |  BC Extra  |  Company News

FDA approves BTG's varicose vein product

BTG plc (LSE:BTG) jumped 63.10p (14%) to 522p on Tuesday after FDA approved an NDA from the company for Varithena (formerly known as Varisolve ) to treat varicose veins. BTG plans to launch the polidocanol...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Clinical News

Varisolve regulatory update

BTG said FDA accepted for review an NDA for Varisolve to treat varicose veins. The company submitted the application in early February. The exact PDUFA date is not disclosed, but BTG said the polidocanol endovenous...
23:54 , Apr 12, 2013 |  BC Extra  |  Company News

FDA to review BTG's Varisolve

BTG plc (LSE:BTG) said FDA accepted for review an NDA for Varisolve to treat varicose veins. The company submitted the application in early February. The exact PDUFA date is not disclosed, but BTG said the...
08:00 , Feb 11, 2013 |  BC Week In Review  |  Clinical News

Varisolve regulatory update

BTG said it submitted an NDA to FDA for Varisolve to treat varicose veins. Last year, BTG said the polidocanol endovenous microfoam ( PEM ) met the primary endpoint of improving patient-reported varicose vein symptoms...
08:00 , Feb 11, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones BTG plc (LSE:BTG) was off 7.4p to 327p last week after submitting an NDA to FDA for Varisolve to treat varicose veins. The product is polidocanol endovenous microfoam. Hemispherx Biopharma Inc. (NYSE-M:HEB) lost...